Company Filing History:
Years Active: 2005
Title: Kevin Hodggetts: Innovator in CNS and Peripheral Disorder Treatments
Introduction
Kevin Hodggetts is a notable inventor based in Killingworth, CT (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that address various central nervous system (CNS) and peripheral disorders. His work has the potential to impact the treatment of conditions such as stress, anxiety, depression, cardiovascular disorders, and eating disorders.
Latest Patents
Hodggetts holds a patent for 2,5-diarypyrimidine compounds. These diarylpyrimidine compounds of Formula I are designed to be useful in treating a range of disorders. The patent also includes methods of treatment and packaged pharmaceutical compositions. Additionally, the compounds are valuable as probes for the localization of corticotropin-releasing factor (CRF) receptors and serve as standards in assays for CRF receptor binding. Methods for utilizing these compounds in receptor localization studies are also detailed in the patent.
Career Highlights
Kevin Hodggetts is associated with Neurogen Corporation, where he has been instrumental in advancing research and development in the pharmaceutical sector. His innovative approach and dedication to improving treatment options for various disorders have established him as a key figure in his field.
Collaborations
Hodggetts has collaborated with notable colleagues such as Jianhua Huang and Dario Doller. Their combined expertise has contributed to the success of their projects and the advancement of their research initiatives.
Conclusion
Kevin Hodggetts is a prominent inventor whose work in developing 2,5-diarypyrimidine compounds showcases his commitment to addressing critical health issues. His contributions to Neurogen Corporation and the pharmaceutical industry highlight the importance of innovation in improving treatment options for patients.